{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.42","upperLimit":"5.00","value":"2.04"},{"groupId":"OG001","lowerLimit":"0.50","upperLimit":"8.08","value":"3.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Tmax is the time to reach maximum observed plasma concentration of metformin alone or in combination with erdafitinib","dispersionType":"Full Range","groups":[{"description":"Participants received single dose of metformin 1000 mg tablet, orally, once daily, starting from Day -1 through Day 14 of Cycle 1 (each cycle length=28 days).","id":"OG000","title":"DDI Study: Metformin 1000 mg Alone"},{"description":"Participants received single dose of metformin 1000 mg tablet, orally, once daily, starting from Day -1 through Day 14 of Cycle 1 along with erdafitinib 8 mg starting from Day 1 up to Day 15 of Cycle 1 (each cycle length=28 days).","id":"OG001","title":"DDI Study: Metformin 1000 mg + Erdafitinib 8 mg"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic analysis set included all participants who received at least 1 dose of study drug and had at least 1 sample collected during treatment to determine the drug concentration. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)","title":"Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Metformin Alone or in Combination With Erdafitinib","type":"PRIMARY","unitOfMeasure":"Hours"}